English, Article edition: Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke: A Canadian Healthcare Perspective Shannon E. Sinclair; Luciana Frighetto; Peter S. Loewen; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/95064
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke: A Canadian Healthcare Perspective
Author
  • Shannon E. Sinclair
  • Luciana Frighetto
  • Peter S. Loewen
  • Rubina Sunderji
  • Philip Teal
  • Susan C. Fagan
  • Carlo A. Marra
Physical Description
  • article
Notes
  • Background: There are over 40 000 ischaemic strokes annually in Canada, which result in significant morbidity, mortality and burden to the healthcare system. A recent, large clinical trial has evaluated tissue plasminogen activator (t-PA) intravenously for the treatment of acute ischaemic stroke with promising outcomes but with an increased risk of symptomatic intracranial haemorrhage. Objective: To compare clinical and economic outcomes of intravenous t-PA therapy (0.9 mg/​kg, to a maximum of 90mg, initiated within 3 hours of stroke onset) versus no t-PA for acute ischaemic stroke based on the outcomes achieved in the National Institute of Neurological Disorders and Stroke (NINDS) trial. Design: A Markov model depicting the natural lifetime course after an initial acute ischaemic stroke. On the basis of this model, a simulated trial compared no t-PA with t-PA. Patients: A hypothetical cohort of 1000 patients with acute ischaemic stroke. Study perspective: Canadian healthcare system. Outcome measures: Total acute stroke and post-stroke treatment costs and cumulative quality-adjusted life-years (QALYs). Results: For a hypothetical cohort of 1000 patients, the estimated lifetime stroke costs were 103 100 000 Canadian dollars ($Can) [1999 values) in the t-PA arm ($Can103 100 per patient) compared with $Can106 900 000 in the no t-PA arm ($Can106 900 per patient), yielding a lifetime cost difference of $Can3 800 000 in favour of t-PA versus no t-PA ($Can3800 per patient). In the hypothetical cohort, t-PA treatment resulted in 13 130 QALYs versus 9670 QALYs with no t-PA treatment. This translated into a net benefit of 3460 additional QALYs per 1000 patients (3.46 QALYs per patient). No treatment, outcome or economic variables influenced the model outcome. Conclusion: From the standpoint of cost effectiveness, treatment of acute ischaemic stroke with intravenous t-PA is an economically attractive strategy.
  • Alteplase, Cost utility, Pharmacoeconomics, Plasminogen activators, Stroke
  • RePEc:wkh:phecon:v:19:y:2001:i:9:p:927-936
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment